NASDAQ · Biotechnology

Belite Bio, Inc (BLTE) Stock

$157.14 -2.45% NASDAQ: BLTE Healthcare

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies.

Valuation

MetricValue
Price$157.14
Market Cap$6.30B
P/E Ratio-61.62
P/B Ratio7.87
P/S Ratio0.00
EPS (TTM)$-2.31
52-Week High$200.00
52-Week Low$60.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-18.14%
ROA-11.13%
ROCE-12.74%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio33.71

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-10.0M$-13.0M$-32.0M$-40.0M$-84.0M
Net Profit$-10.0M$-13.0M$-32.0M$-36.0M$-78.0M
EPS$-0.40$-0.63$-1.19$-1.18$-2.31
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$18.0M$44.0M$95.0M$152.0M$781.0M
Total Liabilities$33.0M$3.0M$4.0M$6.0M$10.0M
Cash$17.0M$42.0M$88.0M$32.0M$353.0M
Borrowings$32.0M$1.0M$1.0M$1.0M$0

Latest News

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference GlobeNewswire · Jul 15, 2026 Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease MarketBeat · Jul 10, 2026 Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium GlobeNewswire · Jul 6, 2026 Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences GlobeNewswire · Jul 6, 2026 Belite Bio Insider Sold Shares Worth $1,405,729, According to a Recent SEC Filing MT Newswires · Jun 17, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-7.0M$-11.0M$-30.0M$-29.0M$-37.0M
Investing Cash Flow$0$-1.0M$0$-111.0M$-305.0M
Financing Cash Flow$0$-1.0M$-1.0M$41.0M$370.0M
Net Cash Flow$-8.0M$25.0M$46.0M$-56.0M$321.0M
Free Cash Flow$-8.0M$-12.0M$-30.0M$-29.0M$-37.0M

Valuation & Return Ratios

MetricValue
PEG Ratio1.15
EV / EBITDA-65.90
FCF Yield-0.00%
Quick Ratio33.71
Interest Coverage0.00
Return 1Y135.19%
Return 3Y314.08%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACAD $28.89 -0.07% 8.94 $4.95B 0.00%
ADMA $9.33 -0.64% 12.17 $2.16B 0.00%
ARQT $23.75 -0.92% -158.54 $2.97B 0.00%
CRNX $84.95 +0.00% -16.80 $9.00B 0.00%
DYN $25.10 -1.30% -7.64 $4.69B 0.00%

About Belite Bio, Inc

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.

Belite Bio, Inc is headquartered in US.

Belite Bio, Inc (BLTE) stock trades at $157.14 with a market capitalization of $6.30B. The stock is valued at a price-to-earnings (P/E) ratio of -61.62, price-to-book of 7.87, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $60.00 and $200.00, and currently trades 21.4% below its 52-week high.

On profitability, Belite Bio, Inc generates a return on equity (ROE) of -18.14%, return on capital employed of -12.74%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: belitebio.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides